Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial

BACKGROUND: Zagotenemab (LY3303560), a monoclonal antibody, preferentially binds to extracellular, misfolded, aggregated tau that has been implicated in Alzheimer’s disease (AD). OBJECTIVE: The goal of this study was to assess the safety and pharmacokinetics of multiple doses of zagotenemab in parti...

Descripción completa

Detalles Bibliográficos
Autores principales: Willis, Brian A., Lo, Albert C., Dage, Jeffrey L., Shcherbinin, Sergey, Chinchen, Louise, Andersen, Scott W., LaBell, Elizabeth S., Perahia, David G.S., Hauck, Paula M., Lowe, Stephen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2023
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578324/
https://www.ncbi.nlm.nih.gov/pubmed/37849628
http://dx.doi.org/10.3233/ADR-230012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578324/
https://www.ncbi.nlm.nih.gov/pubmed/37849628
http://dx.doi.org/10.3233/ADR-230012

Ejemplares similares